Tags

Type your tag names separated by a space and hit enter

Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis.
J Clin Endocrinol Metab. 1988 Sep; 67(3):465-73.JC

Abstract

To determine the influence of estrogenic steroids on serum FSH bioactivity (B) and immunoreactivity (I) and the FSH isoform distribution profiles, we studied normal women during ovulatory menstrual cycles and a patient with gonadal dysgenesis treated with diethylstilbestrol (DES). Four women with ovulatory menstrual cycles, as judged from their serum immunoreactive LH, FSH, progesterone, and estradiol profiles in daily blood samples, had a significant increase in the mean FSH B/I ratio (P less than 0.05) during the midcycle phase of their menstrual cycles. Similarly, in the patient with gonadal dysgenesis the FSH B/I ratio rose significantly (P less than 0.05) after 3 weeks of DES treatment and declined during the posttreatment period. In five additional normal women, serum obtained during the follicular, midcycle, and luteal phases of their menstrual cycles was chromatofocused, and the FSH isoform distribution pattern determined. Sera obtained from the patient with gonadal dysgenesis before, during, and after DES administration were pooled and studied similarly. Chromatofocusing of a human pituitary tumor extract allowed for determination of the FSH B/I ratio in different pH ranges. The highest FSH B/I ratio was found in the more basic fractions (pH range 5.6-6.0) compared to the acidic fractions. During both the midcycle phase of the normal cycles and the DES administration period in the studies of the patient with gonadal dysgenesis, there was a shift of the FSH isoforms (as measured by immunoassay) to the basic pH range. In contrast, the mid- to late luteal phase samples, which had low B/I ratios, had an increase in FSH isoforms in the acidic pH range (less than 4.8). Similarly, in the patient with gonadal dysgenesis FSH isoforms in the basic range were more abundant during the DES treatment period than in the pre- or posttreatment serum pools. Therefore, it appears that endogenous and exogenous estrogenic stimulation alters FSH isoform distribution such that FSH isoforms that are more basic and have increased biological activity are secreted.

Authors+Show Affiliations

Department of Pediatrics, University of Michigan, Ann Arbor 48109.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

3137241

Citation

Padmanabhan, V, et al. "Modulation of Serum Follicle-stimulating Hormone Bioactivity and Isoform Distribution By Estrogenic Steroids in Normal Women and in Gonadal Dysgenesis." The Journal of Clinical Endocrinology and Metabolism, vol. 67, no. 3, 1988, pp. 465-73.
Padmanabhan V, Lang LL, Sonstein J, et al. Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis. J Clin Endocrinol Metab. 1988;67(3):465-73.
Padmanabhan, V., Lang, L. L., Sonstein, J., Kelch, R. P., & Beitins, I. Z. (1988). Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis. The Journal of Clinical Endocrinology and Metabolism, 67(3), 465-73.
Padmanabhan V, et al. Modulation of Serum Follicle-stimulating Hormone Bioactivity and Isoform Distribution By Estrogenic Steroids in Normal Women and in Gonadal Dysgenesis. J Clin Endocrinol Metab. 1988;67(3):465-73. PubMed PMID: 3137241.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis. AU - Padmanabhan,V, AU - Lang,L L, AU - Sonstein,J, AU - Kelch,R P, AU - Beitins,I Z, PY - 1988/9/1/pubmed PY - 1988/9/1/medline PY - 1988/9/1/entrez SP - 465 EP - 73 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 67 IS - 3 N2 - To determine the influence of estrogenic steroids on serum FSH bioactivity (B) and immunoreactivity (I) and the FSH isoform distribution profiles, we studied normal women during ovulatory menstrual cycles and a patient with gonadal dysgenesis treated with diethylstilbestrol (DES). Four women with ovulatory menstrual cycles, as judged from their serum immunoreactive LH, FSH, progesterone, and estradiol profiles in daily blood samples, had a significant increase in the mean FSH B/I ratio (P less than 0.05) during the midcycle phase of their menstrual cycles. Similarly, in the patient with gonadal dysgenesis the FSH B/I ratio rose significantly (P less than 0.05) after 3 weeks of DES treatment and declined during the posttreatment period. In five additional normal women, serum obtained during the follicular, midcycle, and luteal phases of their menstrual cycles was chromatofocused, and the FSH isoform distribution pattern determined. Sera obtained from the patient with gonadal dysgenesis before, during, and after DES administration were pooled and studied similarly. Chromatofocusing of a human pituitary tumor extract allowed for determination of the FSH B/I ratio in different pH ranges. The highest FSH B/I ratio was found in the more basic fractions (pH range 5.6-6.0) compared to the acidic fractions. During both the midcycle phase of the normal cycles and the DES administration period in the studies of the patient with gonadal dysgenesis, there was a shift of the FSH isoforms (as measured by immunoassay) to the basic pH range. In contrast, the mid- to late luteal phase samples, which had low B/I ratios, had an increase in FSH isoforms in the acidic pH range (less than 4.8). Similarly, in the patient with gonadal dysgenesis FSH isoforms in the basic range were more abundant during the DES treatment period than in the pre- or posttreatment serum pools. Therefore, it appears that endogenous and exogenous estrogenic stimulation alters FSH isoform distribution such that FSH isoforms that are more basic and have increased biological activity are secreted. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/3137241/Modulation_of_serum_follicle_stimulating_hormone_bioactivity_and_isoform_distribution_by_estrogenic_steroids_in_normal_women_and_in_gonadal_dysgenesis_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-67-3-465 DB - PRIME DP - Unbound Medicine ER -